Company: REVB
Filing Date: 2025-05-23
Form Type: S-1/A
Source: 0001213900-25-047104
Chunk: 6

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-05-23
Form: S-1/A
Chunk 6
---
 to our Third Amended and Restated Certificate of Incorporation to effect a reverse stock split of our outstanding shares of common stock at a specific ratio within a range of one-for-two (1-for-2) to a maximum of a one-for-fifty (1-for-50) split. Following the special meeting of stockholders and determination by the Board of Directors on the reverse split ratio, we filed a Certificate of Amendment effective on January 28, 2025, which effected a 1-for-16 reverse stock split of our outstanding shares of common stock as of 12:01 a.m. Eastern Standard Time on January 28, 2025. 2024 Reverse Stock Split On January 17, 2024, at a special meeting of stockholders, our stockholders approved a Certificate of Amendment to our Third Amended and Restated Certificate of Incorporation to effect a reverse stock split of our outstanding shares of common stock at a specific ratio within a range of one-for-two (1-for-2) to a maximum of a one-for-fifty (1-for-50) split. On January 22, 2024, we filed the Certificate of Amendment which effected a 1-for-30 reverse stock split of our outstanding shares of common stock as of 12:01 a.m. Eastern Standard Time on January 25, 2024. 1 Business Strategy and Pipeline Revelation is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation’s proprietary formulation of phosphorylated hexaacyl disaccharide (“PHAD ®”) an established Toll-like receptor 4 (TLR4”) agonist that can stimulate the human body’s innate immune response to prevent and treat disease. Our current Gemini based programs consist of: Gemini-AKI, which is being developed for the prevention of AKI; Gemini-CKD for the treatment of CKD; Gemini-PSI, which is being developed for the prevention of PSI; and GEM-PBI as a prevention of infection in severe burn patients requiring hospitalization (our “Product Candidates”). Revelation’s pipeline is summarized in the figure below: The Gemini Platform Our current therapeutic candidates are all based on our proprietary Gemini formulation of PHAD ®, a synthetic version of monophosphoryl lipid A (“MPLA”), that is known to stimulate TLR4. Stimulation of TLR4 via Gemini leads to a more controlled production of varied cytokines and chemokines which modulate the activity of the innate and adaptive immune response,